To understand what AATD is and what the consequences are for an individual with COPD
To identify target clientele who should be tested for AATD
To understand the diagnostic process
To understand the treatment, including augmentation therapy, as well as long-term adherence and lifestyle improvements to live better with AATD
Miriam Barrecheguren, MD, PhD is a pneumologist who currently works at Vall d’Hebron University Hospital in Barcelona. Her main areas of interest include COPD, AATD and mechanical ventilation. She has been a part of Alpha-1 Antitrypsin Deficiency Center at Vall d’Hebron University Hospital since 2013. After earning her Ph.D. in 2016, on the diagnosis and management of COPD and AATD in Primary Care, she fulfilled a research fellow at McGill University and was then granted a Rio Hortega grant to continue her work in Barcelona. She is the Early Career representative for the European Respiratory Society (ERS) in the European Alpha-1 research collaboration (EARCO).
Sébastien Gagnon, MD is a respirologist who has trained at the Institut Universitaire de Cardiologie et Pneumologie de Québec (IUCPQ), in Quebec City. He is currently doing a fellowship at McGill University under the direction of Dr. Jean Bourbeau. His interests are COPD treatment, new approaches for treatment of breathlessness as well as Pulmonary Rehabilitation.